ArticleJournal of medical biochemistry2025
The diagnostic value of microrna-499 in acute myocardial infarction: A systematic review and meta-analysis.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroRNAs in Heart Failure Pathogenesis and Progression: Mechanistic Control, Biomarker Potential, and Translational Perspectives.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The objective of this study was to assess the diagnostic efficacy of MicroRNA-499 in cases of acute myocardial infarction. Methods: On May 6, 2023, four electronic databases PubMed, Embase, Web of Science, and Cochrane Library were searched with no time restriction. Quality assessment was conducted using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). Random-effects metaanalysis was employed to combine sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). The evaluation of publication bias was conducted through the utilization of Deeks' asymmetry test on the funnel plot. Results: The studies that were included in the analysis, encompassing sample sizes ranging from 63 to 1155, exhibited a pooled sensitivity of 0.88 and a specificity of 0.97. The pooled PLR was determined to be 29.78, while the NLRwas found to be 0.13. Furthermore, the pooled DOR was calculated to be 236.10. The area under the curve (AUC) was reported as 0.98. Conclusions: MicroRNA-499 exhibits high sensitivity and specificity for diagnosing Acute Myocardial Infarction, indicating its potential as a valuable diagnostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.